Tofacitinib - Pfizer
Alternative Names: Cp-690,550; CP-690550; Jaquinus; Tasocitinib; Tofacitinib citrate; Tofacitinib XR; Xeljanz; Xeljanz XRLatest Information Update: 22 Dec 2023
At a glance
- Originator Pfizer
- Developer Johns Hopkins University; Oregon Health & Science University; Pfizer; University of Michigan
- Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Irritable bowel syndrome therapies; Nitriles; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Phase III Glioblastoma
- Phase II COVID-19 pneumonia
- Phase I/II Cutaneous lupus erythematosus; Diffuse scleroderma; Systemic lupus erythematosus
- Preregistration Submission Withdrawal Plaque psoriasis
- No development reported Dermatomyositis; Granuloma annulare; Pulmonary sarcoidosis; Sarcoidosis
- Discontinued Asthma; Atopic dermatitis; Crohn's disease; Dry eyes; Irritable bowel syndrome; Renal transplant rejection
Most Recent Events
- 07 Dec 2023 Pfizer completes the phase III trial for Ulcerative-colitis in USA (PO) (NCT04505410)
- 14 Oct 2023 Pooled safety data of Clostridium difficile infection in ulcerative colitis from phase II, phase III and phase IIIb/IV trials presented at the 31st United European Gastroenterology Week (UEGW-2023)
- 31 May 2023 Pharmacodynamics data from a phase III trial in Juvenile rheumatoid arthritis presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023)